BACKGROUND: The guidelines for digital @entity1066 (DUs) management in @entity785 ( @entity785 ) indicate the use of iloprost to induce wound healing and @entity12584 to prevent the onset of new DU. The aim of our study was to evaluate whether the combination treatment may surmount the effect of the single drug. METHODS: We analyzed data regarding 34 @entity1 with @entity785 and at least one active DU persisting despite 6 months of iloprost therapy, and treated for other 6 months with a combination therapy, i.e. iloprost plus @entity12584 . RESULTS: Overall, @entity1 initially presented 69 DUs (58 on the fingers and 11 on the legs). At the end of the study 34 (49.3%) DUs were completely healed (responding, R), 18 (26.1%) started the healing process (partially responding, PR), and 17 (24.6%) did not respond (NR) to therapy. No new DU was recorded and the @entity1066 localized on the legs did not respond to the combination therapy. Finally, data have been analyzed by dividing the @entity1 in two groups according to the @entity82 level on the finger. In the group with mild @entity82 , 83.4% of DUs resulted with showing complete healing while, in the group with severe @entity82 , only 18% of DUs were healed (P = 0.024). CONCLUSION: The treatment with iloprost plus @entity12584 is effective in determining healing of DUs in @entity785 @entity1 with mild @entity82 . Conversely, the severity of skin @entity82 strongly influences the healing process of DUs. The study confirmed the efficacy of @entity12584 to prevent onset of new DUs.

Digital @entity1066 in scleroderma XXXX : A retrospective observational study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity82 :: ('MESH:D005355', 'Disease') :: ['digital skin fibrosis', 'fibrosis'] @entity12584 :: ('MESH:C086232', 'Chemical') :: ['bosentan'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcers'] @entity785 :: ('MESH:D012595', 'Disease') :: ['systemic sclerosis', 'SSc']
@entity1 :: (9606,Species) :: ['patients']
